Oregon Health and Science University Center for Women's Health

Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

Retrieved on: 
Monday, May 23, 2022
Clinical study design, Assistant, LVEF, International Congress on Tuberculosis, OLE, Library classification, Blood pressure, Incidence, Patient, Science, Oregon Health and Science University Center for Women's Health, LVOT, School, European Society of Cardiology, European Heart Journal, Â, Medical school, SAN, Biomarker, Safety, Division, Cytokinetics, Heart failure, Oregon Health & Science University, Research and development, GLOBE, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive data relating to aficamten from REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM Open Label Extension) and the results from two additional analyses of omecamtiv mecarbil from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), all presented in Late-Breaking Science Sessions at Heart Failure 2022, an International Congress of the European Society of Cardiology. The analysis from GALACTIC-HF related to low blood pressure has been simultaneously published in the European Heart Journal.

Key Points: 
  • The analysis from GALACTIC-HF related to low blood pressure has been simultaneously published in the European Heart Journal.
  • These findings add to the growing body of evidence demonstrating that patients with clinical features suggestive of high-risk heart failure respond favorably to omecamtiv mecarbil.
  • Ahmad Masri, M.D., Assistant Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University, presented the first long-term data from REDWOOD-HCM OLE.
  • Patients enrolled in REDWOOD-HCM OLE have completed participation in REDWOOD-HCM, the Phase 2 clinical trial of aficamten.

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

Retrieved on: 
Friday, May 13, 2022
Permanent Damage, Aileron, B cell, Assistant, KOL, Doctor of Science, FRSB, U.S. Securities and Exchange Commission, Annual report, Nasdaq, Webcast, Patient, Form 10-K, Coronavirus, Oregon Health and Science University Center for Women's Health, Private Securities Litigation Reform Act, Therapy, School, ALRN, Investor, Volunteering, University, Leonard M. Miller School of Medicine, Society, Security (finance), GLOBE, Pharmaceutical industry, Medical imaging, Dermatology

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives, today announced that it will host a virtual KOL investor event on Thursday, May 19, 2022, at 4:00 pm ET/ 1:00 pm PT.

Key Points: 
  • BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives, today announced that it will host a virtual KOL investor event on Thursday, May 19, 2022, at 4:00 pm ET/ 1:00 pm PT.
  • A replay of the webcast will be available for 30 days following the presentation.
  • Aileron is a clinical stage chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients lives.
  • Our targeted strategy is designed to selectively protect multiple healthy cell types throughout the body from chemotherapy without protecting cancer cells.

AANA-VirtaMed Collaboration Incorporates Learning Initiative into Virtual Training

Retrieved on: 
Thursday, May 12, 2022
Other Health, Hardware, Training, Medical Devices, Technology, Hospitals, Education, Surgery, Biotechnology, Medical Supplies, FDA, Health, Physician, Geriatric Orthopaedic Surgery & Rehabilitation, Education, Software, Oregon Health and Science University Center for Women's Health, ABOS, Anterior cruciate ligament reconstruction, Surgeon, Doctor of Philosophy, Inertia, Orthopedic surgery, Science, Patient, Health, Arthroscopy, Virtual reality, Department of Computer Science, University of Manchester, Associate, Association, Palpation, ACL, Arthroscopy Association of North America, Research, Initiative, Rehabilitation, AANA, Shoulder, Pathology, PBP, Patella, James Calder (orthopaedic surgeon), Sawbones, Curriculum, Hip, AAOS, CA, Medicine, Medical device, Medical imaging, VirtaMed

The new ACL Reconstruction module includes a new knee model and updated software based on the research findings of the AANA Copernicus Initiative .

Key Points: 
  • The new ACL Reconstruction module includes a new knee model and updated software based on the research findings of the AANA Copernicus Initiative .
  • This Initiative was a 4-year series of research investigations into the merit and impact of the Proficiency Based Progression (PBP) training model.
  • PBP Training dictates that the trainee must acquire and demonstrate basic skill sets before progressing on to more advanced techniques.
  • Together with AANA, AAOS, and ABOS, VirtaMed combined their virtual reality graphics with the Sawbones FAST module for Fundamentals of Arthroscopy Surgery Training.

Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Retrieved on: 
Wednesday, May 4, 2022
ACHM, COVID-19, Drug development, Calendar, Forward-looking statement, Nasdaq, GLOBE, CNS, Company, Applied Genetic Technologies Corporation, AAV, Safety, ARVO, Research, Retina, EZ, Time, Annual report, Central nervous system disease, Patient, Achromatopsia, Association, Risk, Therapy, Association for Research in Vision and Ophthalmology, Form 10-K, Severe cognitive impairment, Neurotology, Oregon Health and Science University Center for Women's Health, Optogenetics, Northwestern Health Sciences University, Assistant, SEC, Oregon Health & Science University, Technology, Annual general meeting, Central nervous system, Pharmaceutical industry, Ophthalmology

GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the presentation of additional positive findings from the ongoing X-linked retinitis pigmentosa (XLRP) Phase 1/2 study of AGTC-501, including 18-month safety and efficacy data, at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting, May 1-4, 2022 in Denver, Colorado.

Key Points: 
  • The data presented at ARVO update previously reported data from this non-randomized, open-label Phase 1/2 study that the Company believes showed both safety and biological activity of AGTC-501 12 months after treatment.
  • The 18-month data appear to show safety and efficacy signals similar to the studys 12-month findings, including improvements to the ellipsoid zone (EZ).
  • In patients with XLRP, the EZ, a defined region within the photoreceptor layer of the retina, degenerates over time and is eventually lost.
  • AGTCs most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with inherited retinal diseases.

Internet2 Names Steve Corbató of Link Oregon Winner of 2022 Rose-Werle Award

Retrieved on: 
Tuesday, May 3, 2022
Library, Ecosystem, University, Twitter, Oregon Health & Science University, Student, Digital divide, Internet2, Health, Portland State University, Legislation, Oregon State University, K-12, Public sector, CIO, Government, Leadership, Learning, Oregon Health & Science University Hospital, University of Utah, CENIC, Education, Science, View, Solution, Oregon Health and Science University Center for Women's Health, Mentorship, Technology, Research, Utah Education Network, CEO, Multimedia, Renewable energy, Management, Online shopping, Michael Corbat

WASHINGTON, May 3, 2022 /PRNewswire/ -- Internet2 today announced that Steven Corbató, executive director of Link Oregon, is the recipient of the 2022 Rose-Werle Award. The award recognizes leaders who have made extraordinary contributions to expanding broadband services access in support of community anchor institutions and increased educational opportunities for all. 

Key Points: 
  • Corbat will be honored at the Internet2 Community Anchor Program's virtual award ceremony at 3 p.m.
  • From his days at Internet2 and beyond, Steve has been a great collaborator and advocate for research and education networks worldwide.
  • It is a true honor to recognize and celebrate Steve Corbat as the 2022 Rose-Werle Award winner."
  • Before joining Link Oregon, Corbat held leadership positions at the Oregon Health and Science University, University of Utah, and Internet2, along with earlier technical roles at the University of Washington and NorthWestNet.

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health Equity and Health Outcomes With Omidubicel at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings

Retrieved on: 
Monday, April 25, 2022
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Transplant, Aplastic anemia, Oregon Health and Science University Center for Women's Health, U.S. Securities and Exchange Commission, COVID-19, Lymphatic system, Security (finance), 2009 Davis Cup, Risk, Patient, LinkedIn, Trial of the century, Technology, TCT, Oregon Health & Science University, FDA, B cell, Cell, Hematology, Poster, Public, Private Securities Litigation Reform Act, Therapy, Division, UPMC, Outcome, Health Leads, Twitter, Cleveland Clinic, Department, HRQOL, SEC, Safety, NAM, Facebook, BLA, Cancer, UCB, PM, HSCT, Duke University Hospital, Time, Phenotype, Oral, Instagram, NK, Black, SPCC, Pharmaceutical industry, Medical device, Medical imaging, Dentistry, Vaccine, Blood

Projected increases in one-year overall survival ranged (with 20% omidubicel use among allo-HCTeligible patients) from 2.5% for whites patients to 6.3% for Black patients.

Key Points: 
  • Projected increases in one-year overall survival ranged (with 20% omidubicel use among allo-HCTeligible patients) from 2.5% for whites patients to 6.3% for Black patients.
  • The study also concluded that higher levels of modeled omidubicel uptake were associated with greater improvements in clinical outcomes and greater reductions in racial disparities.
  • For additional information on Gamida Cell, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn , Twitter , Facebook or Instagram at @GamidaCellTx.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

Healthcare Providers Improve Revenue Cycle, Clinical and Operational Performance With MedeAnalytics

Retrieved on: 
Monday, March 14, 2022
CDI, Industry, Heart, Twitter, Oregon Health & Science University, Physician, Health, Clinical documentation improvement, OHSU, Saas, Exhibition, Oregon Health and Science University Center for Women's Health, Conference, Impact, HIM, Health care, CMI, Diabetes, Ardent Health Services, Lightning, Hospital, Booth, GLOBE, ALOS, Payment, Patient, Yoy, LOS, Solution, RCM, ARR, Independent Healthcare Providers Network, Value, Science, Revenue, CEO, Assistant, LinkedIn, Health insurance, Nightclub, Pharmaceutical industry

RICHARDSON, Texas, March 13, 2022 (GLOBE NEWSWIRE) -- MedeAnalytics , a healthcare analytics software-as-a-service (Saas) leader enabling financial, clinical and operational analytics for healthcare providers and payers, today announced that several leading healthcare organizations have adopted its self-service analytics solutions to improve revenue cycle, clinical and operational performance with measurable value.

Key Points: 
  • RICHARDSON, Texas, March 13, 2022 (GLOBE NEWSWIRE) -- MedeAnalytics , a healthcare analytics software-as-a-service (Saas) leader enabling financial, clinical and operational analytics for healthcare providers and payers, today announced that several leading healthcare organizations have adopted its self-service analytics solutions to improve revenue cycle, clinical and operational performance with measurable value.
  • "MedeAnalytics is committed to delivering measurable value to its industry leading customers across Healthcare Providers and Payers and help them improve performance and outcomes in the post-pandemic 'new normal'," said Steve Grieco, CEO of MedeAnalytics.
  • MedeAnalytics is a leader in healthcare analytics, providing innovative solutions that enable measurable impact for healthcare payers and providers.
  • With the most advanced data orchestration in healthcare, payers and providers count on us to deliver actionable insights that improve financial, operational, and clinical outcomes.

Nuvalent to Present New Preclinical Data on ROS1-Selective Inhibitor NVL-520 and ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
Nasdaq, AACR, Clinical trial, American Association for Cancer Research, Twitter, Large-cell lung carcinoma, Drug development, TRK, Risk, Private Securities Litigation Reform Act, Company, OR, Research, U.S. Securities and Exchange Commission, Tropomyosin, Cancer, Northwestern Health Sciences University, Mutation, Date, CNS, Chemistry, Multimedia, Brain, Neuroblastoma, Oregon Health and Science University Center for Women's Health, Patient, Health, Security (finance), American Association, B-cell lymphoma, ROS1, COVID-19, Neoplasm, Time, Association, CT, ALK, NSCLC, LinkedIn, Pharmaceutical industry, Communications satellite

Data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 from April 8-13 in New Orleans.

Key Points: 
  • Data will be presented in two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 from April 8-13 in New Orleans.
  • NVL-520 is currently under investigation in the Phase 1/2 ARROS-1 study ( NCT05118789 ) for advanced ROS1-positive NSCLC and other solid tumors, including those with resistance mutations.
  • The second poster characterizes NVL-655 alongside other ALK inhibitors in ALK-driven cancer models beyond NSCLC such as anaplastic large cell lymphoma and neuroblastoma.
  • A Phase 1/2 clinical trial of NVL-655 in patients with advanced ALK-positive NSCLC and other solid tumors is planned for the first half of 2022.

Sameday Health Welcomes Shilena Battan as Chief People Officer

Retrieved on: 
Tuesday, February 15, 2022
People, Cozy, Pepperdine University, COVID, Color, Health, Solution, Business administration, Hope, CPO, CoStar Group, Oregon Health Authority, Workforce, Culture, Pacific University, Acqui-hiring, Acquisition, Vacasa, Research, Multimedia, Gaps, COVID-19, Workplace, MBA, Prosper Portland, Oregon Health and Science University Center for Women's Health, Management, Medicine

LOS ANGELES, Feb. 15, 2022 /PRNewswire/ -- SamedayHealth , the nationwide healthcare provider that specializes in personalized medical treatments and COVID-19 services, today announced that it has named Shilena Battan as Chief People Officer.

Key Points: 
  • LOS ANGELES, Feb. 15, 2022 /PRNewswire/ -- SamedayHealth , the nationwide healthcare provider that specializes in personalized medical treatments and COVID-19 services, today announced that it has named Shilena Battan as Chief People Officer.
  • As CPO, Battan will be responsible for the company's strategy to attract, develop, and retain extraordinary talent with a focus on building a thriving Sameday Health team and culture.
  • As a woman of color, Battan is passionate about bringing diversity, equity, and inclusion into the workplace.
  • "As a hyper-growth healthcare company, we've always believed our work at Sameday Health must be guided by a deep commitment to people, our clients, and our employees," said Sameday Health CEO Felix Huettenbach.

Annals of Family Medicine: Telementoring Program with Chat Box Feature Helps Meet Clinicians' Needs for Information, Resources and Peer Support

Retrieved on: 
Tuesday, January 25, 2022
COVID-19, ANN, Maslow, ECHO, Oregon Health and Science University Center for Women's Health, Program, Investment, National Association Medical Staff Services, Public health, Oregon Health & Science University, Multimedia, Patient, GÉANT, Online shopping

The ECHO program, created in March 2020, included 11 sessions with researchers encouraging interactions among the hundreds of participants via a chat box.

Key Points: 
  • The ECHO program, created in March 2020, included 11 sessions with researchers encouraging interactions among the hundreds of participants via a chat box.
  • Their objective was to assess how chat box communications could provide support to clinicians during the pandemic.
  • The chat box supported many clinicians' needs during a rapidly changing healthcare environment, including the ability to ask questions and provide comments.
  • Many participants also used the platform to marshal additional resources and support for patients from marginalized groups, or for those with special health needs.